Nomura raises ICICI Bank stock price target to INR1,620 on earnings

Nomura/Instinet raised its price target on ICICI Bank to INR1,620 from INR1,535 while maintaining a Buy rating after the bank reported Q4 FY2026 PAT of INR137 billion, 8% YoY and 21% QoQ growth, 11% above estimate. The beat was driven by lower credit costs at 3 bps versus 42 bps expected and stronger net interest income, while loan growth accelerated to 16% YoY and NIMs held at 4.2%. Fee income was soft, but the overall earnings and margin performance support a constructive outlook.

Analysis

The real signal here is not the headline beat; it is the combination of accelerating loan growth with unusually benign credit costs. That mix tends to pull forward consensus upgrades, but the market usually pays up for it only when deposit growth and margin stability confirm it is durable rather than cyclical. The one-off tax-refund benefit makes the margin print look cleaner than it is, so the next two quarters will matter more than the last one for whether the re-rating extends.

For the Indian banking group, the second-order benefit is competitive: if ICICI keeps growing loans at mid-teens while preserving liquidity, smaller private banks and some PSU lenders are forced either to loosen underwriting or give up share. That is especially relevant in retail and SME credit, where lower credit costs can be copied only if underwriting discipline is still intact. The risk is that fee softness is an early warning that the mix is shifting toward lower-yielding or more rate-sensitive lending, which would cap upside if deposit costs re-accelerate.

On the sell side, the current setup is more bullish for quality-large-cap banks than for broader financials because the market will likely reward visible earnings durability over pure growth. The main contrarian angle is valuation: the stock already screens as expensive relative to fair value, so the incremental multiple expansion from here needs either a sustained ROE inflection or a broader India banking rerating. If credit costs normalize back toward a more ordinary run rate over the next 1-2 quarters, a lot of the earnings surprise will compress quickly.

The NMR mention is a red herring for the stock-specific signal, but it reinforces that analysts are still upgrading select large-cap banks on bottom-up earnings power rather than macro beta. That suggests the better trade is to own the cleanest compounding balance sheets and fade weaker lenders that will struggle to match growth without sacrificing margins or asset quality.

Key Decisions for Investors

• Stay long IBN, but use strength to size into a measured position only: best risk/reward is on any 3-5% pullback over the next 1-2 weeks, with a 3-6 month hold if credit costs stay below normalized levels.
• Buy IBN Jan-2026 call spreads rather than outright calls to monetize upside from estimate revisions while capping valuation risk; this is preferable given the stock’s already rich multiple.
• Pair trade: long IBN / short a weaker Indian private bank basket over the next 1-2 quarters to express quality-outperformance if deposit competition rises and asset-quality dispersion widens.
• Tighten stops on any IBN long if next quarter shows deposit growth lagging loan growth by more than ~400 bps or if fee income remains weak for a second consecutive print; that would signal earnings quality deterioration.
• Avoid chasing broad bank-sector beta; prefer idiosyncratic winners with balance-sheet strength, since the near-term upside in this setup comes from sustained earnings revisions, not macro expansion.